⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 19, 2024MedicinaOpen Access

Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients

Akiko Kin Takahiro Mizukami Satoru Ueno Soichiro Mishima Yoshikazu Shimomura

View Full Paper

Ask AI

Bookmark

Share

Abstract

: In this study, our objective was to assess and compare the changes in visual and structural outcomes among patients with neovascular age-related macular degeneration (nAMD) who were switched from intravitreal aflibercept (IVA) to either intravitreal brolucizumab (IVBr) or intravitreal faricimab (IVF) injections in a clinical setting.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kin et al. (2024) studied this question.

synapsesocial.com/papers/68e5fb74b6db64358758f355 https://doi.org/10.3390/medicina60071170

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Short-term Comparison of Switch to Brolucizumab or Faricimab in Eyes with Aflibercept-Resistant Neovascular AMD2024 · 3 citations
2One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment2024 · 18 citations
3Comparison of morphological and functional parameters after switching therapy from brolucizumab to faricimab in neovascular age-related macular degenerationCohort Study · 2026
4Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration2025 · 8 citations
5Efficacy of Initial Intravitreal Faricimab Injection after Switching from Aflibercept to Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration.2025